Clinical Trial Update: A Study of Mirikizumab (LY3074828) in Pediatric Participants With Crohn's Disease [Phase 3]

View source ↗

Summary

A pediatric Phase 3 trial of mirikizumab (LY3074828) for Crohn's disease is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Crohn Disease

Drugs mentioned

• Mirikizumab (mirikizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Crohn's Disease | Phase 3 | Status: RECRUITING